IRIS
BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.303
NA - Nord America 1.934
AS - Asia 1.758
SA - Sud America 628
AF - Africa 65
Continente sconosciuto - Info sul continente non disponibili 16
Totale 6.704
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.869
IE - Irlanda 942
SG - Singapore 633
BR - Brasile 495
HK - Hong Kong 387
SE - Svezia 310
RU - Federazione Russa 273
VN - Vietnam 267
CN - Cina 243
IT - Italia 240
UA - Ucraina 222
DE - Germania 145
AR - Argentina 66
ID - Indonesia 60
CA - Canada 34
BD - Bangladesh 32
KR - Corea 31
GB - Regno Unito 30
FR - Francia 28
IN - India 25
EC - Ecuador 24
ZA - Sudafrica 23
FI - Finlandia 22
MX - Messico 21
BE - Belgio 19
BJ - Benin 19
EU - Europa 15
PY - Paraguay 14
AT - Austria 13
IQ - Iraq 12
JP - Giappone 11
VE - Venezuela 11
CO - Colombia 10
MA - Marocco 8
PL - Polonia 8
RO - Romania 8
CZ - Repubblica Ceca 7
ES - Italia 7
IR - Iran 6
SA - Arabia Saudita 6
TR - Turchia 6
IL - Israele 5
KE - Kenya 5
LT - Lituania 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
CL - Cile 4
NL - Olanda 4
NP - Nepal 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
DZ - Algeria 3
JM - Giamaica 3
KZ - Kazakistan 3
PH - Filippine 3
PK - Pakistan 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AL - Albania 2
CH - Svizzera 2
DK - Danimarca 2
EG - Egitto 2
GT - Guatemala 2
HU - Ungheria 2
JO - Giordania 2
NO - Norvegia 2
PE - Perù 2
QA - Qatar 2
TN - Tunisia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
KG - Kirghizistan 1
LB - Libano 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
SV - El Salvador 1
TH - Thailandia 1
TW - Taiwan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.704
Salva come PNG Salva come JPEG
Città #
Dublin 927
Hong Kong 387
Jacksonville 372
Singapore 204
Beijing 156
Wilmington 119
Lawrence 118
Princeton 118
Chandler 108
San Mateo 106
Ho Chi Minh City 100
Moscow 97
Ashburn 88
Los Angeles 73
Munich 56
São Paulo 49
Hanoi 44
Buffalo 43
Redondo Beach 31
Seoul 31
Dong Ket 30
Jakarta 30
Piemonte 26
Ann Arbor 25
Boardman 23
Dallas 23
Cotonou 19
New York 19
Santa Clara 19
Brussels 18
Novara 17
Houston 16
Nuremberg 15
Milan 14
Montreal 14
Norwalk 14
Rio de Janeiro 14
Helsinki 13
Johannesburg 12
Toronto 12
Turin 12
Tokyo 11
Dhaka 10
Guayaquil 10
Porto Alegre 10
Tianjin 10
Da Nang 9
Frankfurt am Main 9
Haiphong 9
London 9
Turku 9
Andover 8
Belo Horizonte 8
Falkenstein 8
Quito 8
Warsaw 8
Brasília 7
Denver 7
Hải Dương 7
Thái Bình 7
Alessandria 6
Biên Hòa 6
Brno 6
Brooklyn 6
Curitiba 6
Fairfield 6
Horia 6
Mexico City 6
Rome 6
San Diego 6
San Francisco 6
Vienna 6
West Jordan 6
Woodbridge 6
Buenos Aires 5
Campinas 5
Caracas 5
Casablanca 5
Chennai 5
Franca 5
Grafing 5
Indaiatuba 5
Monza 5
Mülheim 5
Nairobi 5
Naples 5
Palermo 5
Seattle 5
Boston 4
Cambridge 4
Canoas 4
Cape Town 4
Congonhas 4
Cuiabá 4
Durban 4
Elk Grove Village 4
Goiânia 4
Guarulhos 4
Leawood 4
Paris 4
Totale 3.978
Salva come PNG Salva come JPEG
Nome #
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 205
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 149
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 138
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 83
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 82
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 80
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 77
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 76
Coinfection with other respiratory pathogens in COVID-19 patients 76
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 76
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 75
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir 75
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients 74
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia 72
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 71
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 70
Ceftobiprole perspective: Current and potential future indications 70
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon] 67
Prevalenza e fattori di rischio dell'insorgenza di psicosi acuta 59 nei pazienti anziani ospedalizzati per infezione da Sars-COV-2: studio retrospettivo 67
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 66
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 65
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir 65
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 65
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 64
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 63
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 63
The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results? 62
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 61
Combination therapy in chronic hepatitis B: what are the real benefits? 61
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy 61
Lo studio filologico applicato alla descrizione della “pestilenza” di Atene di Tucidide: dall’analisi del testo agli aspetti di epidemiologia e malattie infettive 60
Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir 60
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 60
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 59
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 59
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 59
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 58
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 57
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 56
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 56
Long-COVID syndrome in hospitalized patients after 2 years of follow-up 55
Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study 55
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 54
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? 54
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 54
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 54
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 54
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 53
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 53
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 52
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 52
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 52
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 51
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 51
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 51
Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? 51
Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis 50
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes 50
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 50
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 50
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 50
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 50
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis 50
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 49
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools 49
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 49
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E 49
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 48
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 48
Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group 48
A rare SARS-CoV-2 complication: Candida spondylodiscitis following SARS-CoV-2 infection—two case reports 47
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 47
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 47
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 47
Letter: liver involvement and mortality in COVID-19—the role of anti-viral therapy should be considered 47
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 47
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 46
Klebsiella pneumoniae meningitis in a 38-year-old Chinese traveller with impaired glucose tolerance: A new emerging syndrome? 46
Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis 46
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon 46
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 46
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 45
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment 45
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 45
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 44
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 44
Clinical characteristics and outcomes in hospitalized patients with West Nile neuroinvasive disease: A case-series analysis 43
Behavioural health issues in post coronavirus disease (COVID) syndrome and suicide risk: a narrative review 43
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 43
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers 43
Le coinfezioni in epatologia 43
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 42
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 42
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 42
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 42
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 42
Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia 42
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 42
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 41
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study 41
Totale 5.825
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021382 0 0 0 0 0 15 102 10 102 4 109 40
2021/2022673 8 10 126 47 20 21 27 16 93 24 120 161
2022/20231.564 135 111 89 24 36 89 33 61 913 13 44 16
2023/2024441 26 19 18 9 64 6 116 15 13 10 7 138
2024/20251.438 14 11 100 25 14 67 186 157 432 201 40 191
2025/20261.971 176 206 445 828 278 38 0 0 0 0 0 0
Totale 6.852